Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are finding the best dose of CUSP06 to use in people with advanced ovarian or endometrial cancer. The people in this study have cancer that came back or keeps growing after treatment.
Researchers want to find the best dose of ziftomenib to give with imatinib in people with advanced gastrointestinal stromal tumors (GIST). The people in this study have GIST that keeps growing after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to learn if canakinumab can prevent cancer from developing in people with clonal cytopenia of undetermined significance (CCUS). In CCUS, there is a mutation (change) in one or more of the genes that help blood cells develop. People with CCUS have low levels of certain kinds of blood cells.
Doctors routinely use intensity-modulated radiation therapy (IMRT) after surgery to treat squamous cell carcinoma (cancer) of the tongue. IMRT delivers radiation directly to cancer cells from different angles by changing the radiation beam into multiple smaller beams. By targeting the tumor more precisely, IMRT reduces radiation damage to healthy tissue.
Researchers in this study want to determine if combining the drug venetoclax with standard chemotherapy may be more effective than standard chemotherapy alone in children and adolescents with relapsed acute myeloid leukemia (AML). Venetoclax blocks Bcl-2, a protein that helps cancer cells to survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and/or make other treatments more effective.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are studying how casdatifan, alone or with zimberelimab, works in people with kidney cancer. The people in this study have clear cell renal cell carcinoma. Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery).
Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.
Researchers are finding the best dose of MB-CART19.1 immunotherapy in people with lymphoma. The people in this study have central nervous system lymphoma (CNSL) that came back or keeps growing after treatment.
